Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer
US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for (…)
Site référencé:
The Guardian
5600.jpg?width=140&quality=85&auto=format&fit=max&s=3c9fbe44095ac082c7d3ab69690c3997, 5600.jpg?width=460&quality=85&auto=format&fit=max&s=cfb59dc39e88893fa40a3c4f100554b7, 5600.jpg?width=700&quality=85&auto=format&fit=max&s=a68123dfb611648b76cc65a9b7551f47
The Guardian
Volkswagen indicates shortage of Chinese chips would hit profits
30/10/2025
Max Dowman’s journey from Billericay to making history with Arsenal
30/10/2025
Warming whites ? Break away from the ice bucket this winter | Hannah Crosbie on drinks
30/10/2025
The least frightening films ever – ranked !
30/10/2025
The luxury effect : why you’ll find more wildlife in wealthy areas – and what it means for your health
30/10/2025
Selling the left’s message in the digital age is an art – Ireland’s new president mastered it | Una Mullally
30/10/2025